A committee of experts from the American Medicines Agency (FDA) has come out in favor of the sale of Flibanserin in the United States.
Intended for pre-menopausal women suffering from a lack of sexual desire, this drug, which had been rejected twice, in 2010 and 2013, this time was approved by the experts of the committee at the rate of 18 votes once morest six. A vote in favor of the marketing of the drug which even caused applause in the meeting room, which was public.
According to one of the clinical trials conducted, women on Flibanserin reported having an average of 4.4 satisfying sexual experiences in one month, compared to 3.7 in the placebo group and 2.7 before the start of the study.
